share_log

Lineage Cell Therapeutics: Q4 Earnings Insights

Lineage Cell Therapeutics: Q4 Earnings Insights

Lineage Cell Therapeutics:第四季度收益洞察
Benzinga ·  03/07 16:05

Lineage Cell Therapeutics (AMEX:LCTX) reported its Q4 earnings results on Thursday, March 7, 2024 at 04:01 PM.

Lineage Cell Therapeutics(美國證券交易所股票代碼:LCTX)於2024年3月7日星期四下午4點01分公佈了其第四季度業績。

Here's what investors need to know about the announcement.

以下是投資者需要了解的有關該公告的信息。

Earnings

收益

Lineage Cell Therapeutics beat estimated earnings by 25.0%, reporting an EPS of $-0.03 versus an estimate of $-0.04.

Lineage Cell Therapeutics的收益比預期高出25.0%,每股收益爲-0.03美元,而估計爲-0.04美元。

Revenue was up $200 thousand from the same period last year.

收入比去年同期增長了20萬美元。

Past Earnings Performance

過去的收益表現

Last quarter the company missed on EPS by $0.0 which was followed by a 3.0% drop in the share price the next day.

上個季度,該公司的每股收益下跌了0.0美元,隨後第二天股價下跌了3.0%。

Here's a look at Lineage Cell Therapeutics's past performance:

以下是Lineage Cell Therapeutics過去的表現:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate -0.04 -0.04 -0.04 -0.04
EPS Actual -0.04 -0.03 -0.03 -0.03
Revenue Estimate 2.59M 2.20M 2.01M 2.57M
Revenue Actual 1.25M 3.23M 2.39M 1.90M
季度 2023 年第三季度 2023 年第二季度 2023年第一季度 2022 年第四季度
每股收益估算 -0.04 -0.04 -0.04 -0.04
實際每股收益 -0.04 -0.03 -0.03 -0.03
收入估算 2.59 億 2.20M 2.01M 2.57M
實際收入 1.25 米 3.23 M 2.39 M 1.90 米

To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar here.

要追蹤Lineage Cell Therapeutics發佈的所有業績,請在此處訪問他們的業績日曆。

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文由Benzinga的自動內容引擎生成,並由編輯審閱。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論